Report 1: Negotiation-Naïve & No Interest in Negotiating a Private Payer PLA
PDCI Market Access (PDCI) and H3 Consulting (H3) conducted an online survey of a select group of Canadian pharmaceutical manufacturer and private payer stakeholders to provide clarity on the evolving private payer product listing agreement (PLA) landscape. We thank those 27 individuals respondents for taking the time to contribute and provide their valuable insights for this project.
The purpose of this survey, which was conducted between June 29, 2015 and July 17, 2015, was to enhance the understanding of the prevalence, objectives, and content of such PLAs. Over the coming weeks, we will be issuing four reports focusing on the varied stakeholder perspectives surrounding interest, experience, and expectations surrounding private payer PLA negotiations.
- Report 1: Negotiation-Naïve & No Interest in Negotiating a Private Payer PLA
- Report 2: Negotiation Naïve & Interested in Negotiating a Private Payer PLA
- Report 3: Experience Negotiating Private Payer PLAs
- Report 4: PLA Perspectives, Comparison and Contrast
Please click here for a complimentary copy of ‘Report 1: Negotiation-Naïve & No Interest
in Negotiating a Private Payer PLA.’